Literature DB >> 4479366

The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.

H T Mouridsen, O Faber, L Skovsted.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4479366     DOI: 10.1111/j.1600-0773.1974.tb00729.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


× No keyword cloud information.
  17 in total

Review 1.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

2.  The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man.

Authors:  O K Faber; H T Mouridsen; L Skovsted
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

3.  Pharmacokinetics of cyclophosphamide in Kenyan Africans.

Authors:  F Juma; T Ogada
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

4.  Haemodialysis during cyclophosphamide treatment.

Authors:  R A Milsted; M Jarman
Journal:  Br Med J       Date:  1978-04-01

5.  Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

6.  Detection of contamination with antineoplastic agents in a hospital pharmacy department.

Authors:  P J Sessink; R B Anzion; P H Van den Broek; R P Bos
Journal:  Pharm Weekbl Sci       Date:  1992-02-21

7.  Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice.

Authors:  M R Nowrousian; C G Schmidt
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

8.  The disposition of cyclophosphamide in a group of myeloma patients.

Authors:  V Bramwell; R T Calvert; G Edwards; H Scarffe; D Crowther
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

9.  Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.

Authors:  P M Wilkinson; P A O'Neill; N Thatcher; S B Lucas
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

10.  [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].

Authors:  T Wagner; D Heydrich; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1980-01       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.